阿托伐他汀序贯治疗对急性ST段抬高型心肌梗死直接PCI治疗患者血清IL-6和hs-CRP的影响

被引:18
作者
李尚俭 [1 ]
邓争荣 [1 ]
吕晓莉 [2 ]
官功昌 [1 ]
张国梅 [1 ]
机构
[1] 陕西省人民医院心内一科
[2] 陕西省人民医院检验科
关键词
阿托伐他汀钙; 急性ST段抬高型心肌梗死; 经皮冠状动脉介入治疗; 白细胞介素-6; 高敏C反应蛋白;
D O I
暂无
中图分类号
R542.22 [];
学科分类号
1002 ; 100201 ;
摘要
目的探讨经皮冠状动脉介入治疗(PCI)围手术期阿托伐他汀序贯治疗对急性ST段抬高型心肌梗死(STEMI)患者血清白细胞介素-6(IL-6)和高敏C反应蛋白(hs-CRP)浓度的影响。方法 76例接受急诊PCI的STEMI患者随机分为A组(n=26)、B组(n=26)和C组(n=24)。A组给予阿托伐他汀钙20 mg,1次/d;B组给予阿托伐他汀钙80 mg PCI术前30 min顿服,术后20 mg,1次/d;C组术前同B组,术后给予阿托伐他汀钙40 mg,1次/d。于术前即刻及术后1,3,7 d测定血清肌酸激酶同工酶(CK-MB)、肌钙蛋白T(cTnT)、IL-6和hs-CRP水平。结果术前三组间患者血清CK-MB、cTnT、IL-6和hs-CRP水平无统计学差异(P>0.05),术后1 d均较术前增高(P<0.05)。PCI治疗后3 d,CK-MB、cTnT和IL-6水平开始下降,血清hs-CRP水平仍呈升高趋势(P<0.05)。PCI治疗后7 d,各组CK-MB、cTnT较术前均有下降(P<0.05),IL-6和hs-CRP较术后3 d明显下降(P<0.05),B组和C组血清CK-MB、cTnT、IL-6和hs-CRP水平较A组下降明显(P<0.05),且C组较B组更为明显(P<0.05)。结论 STEMI患者PCI围术期使用大剂量阿托伐他汀序贯治疗短期即可显著降低血清炎性因子,减少心肌损伤。
引用
收藏
页码:662 / 665
页数:4
相关论文
共 5 条
[1]   阿托伐他汀非调脂作用的最新进展 [J].
孙姗 ;
吴尚勤 .
中国临床药理学与治疗学, 2006, (02) :141-144
[2]  
Depression, C-reactive Protein and Two-year Major Adverse Cardiac Events in Men after Acute Coronary Syndromes[J] . Biological Psychiatry . 2007 (4)
[3]  
Atorvastatin Pretreatment Improves Outcomes in Patients With Acute Coronary Syndromes Undergoing Early Percutaneous Coronary Intervention[J] . Giuseppe Patti,Vincenzo Pasceri,Giuseppe Colonna,Marco Miglionico,Dionigi Fischetti,Gennaro Sardella,Antonio Montinaro,Germano Di Sciascio.Journal of the American College of Cardiology . 2007 (12)
[4]  
Coronary Stenting and Inflammation: Implications for Further Surgical and Medical Treatment[J] . Walter J. Gomes,Enio Buffolo.The Annals of Thoracic Surgery . 2006 (5)
[5]  
Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study[J] . Vincenzo Pasceri,Giuseppe Patti,Annunziata Nusca,Christian Pristipino,Giuseppe Richichi,Germano Di Sciascio.Circulation . 2004 (6)